 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...1314151617181920212223...123124» |
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial. (Hall A; Poster Bd #: 219) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1691;
P3
Treatment-na
- Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC). (S100bc) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1681;
In the very favorable risk population, there was a statistically significant decrease in 2 year overall survival with IPI-NIVO (HR 3.19) which, if validated, could underline the necessity of targeting the VEGF pathway in this population. Further prospective trials and longer follow-up are required to confirm these findings.
- A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma. (S100bc) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1679;
In this observational analysis, patients with targeted doublet regimens had a higher median TTF and OS compared to those receiving monotherapies. We continue to build on this dataset and plan to conduct progression free survival analysis.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Randomized phase II trial of pembrolizumab/lenvatinib (P+L) +/- responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL). (Hall A; Poster Bd #: 387a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_912;
P2
This design has a type I error rate 0.10 and power 0.8 when the true response rate is 0.25. Enrollment has commenced.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update. (Hall A; Poster Bd #: 364) - Apr 24, 2024 - Abstract #ASCO2024ASCO_885;
Updated results confirmed that the combination of pembrolizumab plus lenvatinib as neoadjuvant therapy had moderate anti-tumor efficacy in resectable mucosal melanoma. Increased CD8+ T cell infiltration was observed in tumor with pathologic response, supporting further investigation in mucosal melanoma.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response. (Hall A; Poster Bd #: 350) - Apr 24, 2024 - Abstract #ASCO2024ASCO_874;
P2
MPR pts had a higher density of T cells in the TME at baseline, and a more differentiated and activated immune profile after neoIT compared with non-MPR pts. MPR pts had a significant increase in the number of lymphoid aggregates at week 6 compared to non-MPR pts; however, the role of these lymphoid aggregates, including the follicular B helper T cell subset and mature B cells, promoting a good pathological response to neoIT is yet to be clarified.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti (Hall A; Poster Bd #: 343) - Apr 24, 2024 - Abstract #ASCO2024ASCO_867;
P2
MPR pts had a significant increase in the number of lymphoid aggregates at week 6 compared to non-MPR pts; however, the role of these lymphoid aggregates, including the follicular B helper T cell subset and mature B cells, promoting a good pathological response to neoIT is yet to be clarified. With over 4 years of follow up, len + pembrocontinued to show antitumor activity in pts with advanced melanoma and confirmed progression after ?2 doses of anti
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: Lenvamel, a multicenter retrospective study of the French Group of Skin Cancers. (Hall A; Poster Bd #: 330) - Apr 24, 2024 - Abstract #ASCO2024ASCO_855;
Pts pre-treated with anti-PD-1+ anti-CTLA-4, and those with BRAF wild-type melanoma seemed to benefit more from this strategy. Our study also provides promising data (considering the small sample) for pts with mucosal melanoma.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. (Hall A; Poster Bd #: 307) - Apr 24, 2024 - Abstract #ASCO2024ASCO_833;
FDG-PET demonstrates utility in predicting pathological response and survival with neoadjuvant immunotherapy in melanoma. PET may identify pts who are not going to be pathological responders and who have the worst survival outcomes, enabling a potential switch of neoadjuvant systemic therapy.
- Keytruda (pembrolizumab) / Merck (MSD)
Triplet combination treatments with pembrolizumab (pembro) for anti (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_824;
P1/2
We report results from arm 1 (pembro + quavonlimab [qmab] (anti-CTLA4) + vibostolimab [vibo] (anti-TIGIT)), arm 2 [pembro + qmab + lenvatinib [len] (TKI)), and arm 3 (pembro + ATRA [all-trans retinoic acid]) of KEYMAKER-U02A. Although objective responses were observed in some pts with anti
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) (clinicaltrials.gov) - Apr 24, 2024
P3, N=196, Recruiting, Sponsor: Wen Tianfu
Although objective responses were observed in some pts with anti Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> May 2027
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Commentary: Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases. (Pubmed Central) - Apr 22, 2024
Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> May 2027 No abstract available
- || Clinical, Retrospective data, Review, Journal, Metastases: The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis. (Pubmed Central) - Apr 22, 2024
Concerning OS benefits, sintilimab plus bevacizumab biosimilar (Sint?+?Beva), camrelizumab plus rivoceranib (Camre?+?Rivo), and lenvatinib plus pembrolizumab (Lenva?+?Pemb) appear to exhibit similar effects to Tre?+?Du and Atezo?+?Beva...With lower incidence rates of treatment-related adverse events and non-inferior efficacy compared to sorafenib, ICI monotherapies should be prioritized as a first-line treatment approach for patients who are not suitable candidates for ICI-combined therapies. PROSPERO, CRD42022288172.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Combination therapy: Lichen Planus Pemphigoides Induced by Camrelizumab in Combination With Lenvatinib. (Pubmed Central) - Apr 22, 2024
PROSPERO, CRD42022288172. No abstract available
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. (Pubmed Central) - Apr 19, 2024
The most frequent G1 toxicity was diarrhea (24%), G2 was fatigue (30%), and hypertension and skin toxicity (6%) for G3. Our findings suggest a clinically relevant effectiveness of lenvatinib plus everolimus combination with an acceptable toxicity profile for heavily pretreated patients with mRCC.
- | Enrollment open: CARE1 Pragmatic Clinical Trial (clinicaltrials.gov) - Apr 18, 2024
P3, N=1250, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Our findings suggest a clinically relevant effectiveness of lenvatinib plus everolimus combination with an acceptable toxicity profile for heavily pretreated patients with mRCC. Not yet recruiting --> Recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (clinicaltrials.gov) - Apr 18, 2024
P1/2, N=400, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer (clinicaltrials.gov) - Apr 18, 2024
P2, N=20, Recruiting, Sponsor: Saint Petersburg State University, Russia
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Observational data, Journal, PD(L)-1 Biomarker: Predicting Response to Immunotargeted Therapy in Endometrial Cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study. (Pubmed Central) - Apr 17, 2024
The sensitivity and specificity of these biomarkers were 85.71% and 70.59%, and 85.71% and 85.71%, respectively. The proportion of CD20+ B lymphocytes and the CD8-to-CD20 lymphocytes ratio in the stroma of endometrial cancer serves as both a prognostic marker of response to immunotargeted therapy and a prognostic factor for progression-free survival in patients.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: MK-7902-010 China Extension: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension (clinicaltrials.gov) - Apr 17, 2024
P3, N=112, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
The proportion of CD20+ B lymphocytes and the CD8-to-CD20 lymphocytes ratio in the stroma of endometrial cancer serves as both a prognostic marker of response to immunotargeted therapy and a prognostic factor for progression-free survival in patients. Trial completion date: Jul 2026 --> Mar 2025 | Trial primary completion date: Jul 2026 --> Aug 2023
- | Trial completion date, Trial primary completion date: Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Apr 16, 2024
P1, N=20, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial completion date: Jul 2026 --> Mar 2025 | Trial primary completion date: Jul 2026 --> Aug 2023 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- ||| SAL008 / Shenzhen Salubris
Enrollment change, Monotherapy: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - Apr 16, 2024
P1/2, N=263, Recruiting, Sponsor: Salubris Biotherapeutics Inc
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 N=149 --> 263
- |||||||||| Kaitanni (cadonilimab) / Akesobio
New P3 trial, Combination therapy, Metastases: AK104-308: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 16, 2024
P3, N=469, Not yet recruiting, Sponsor: Akeso
- || AiTan (rivoceranib) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Retrospective data, Review, Journal, Metastases: Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials. (Pubmed Central) - Apr 16, 2024
N=149 --> 263 Our network meta-analysis showed that we believe that cabozantinib has the potential to become a widely used drug in clinical practice.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Apr 16, 2024
P1, N=11, Active, not recruiting, Sponsor: Yousef Zakharia
Our network meta-analysis showed that we believe that cabozantinib has the potential to become a widely used drug in clinical practice. Trial completion date: Sep 2024 --> Jun 2028
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Checkpoint inhibition: Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma. (Pubmed Central) - Apr 15, 2024
Additionally, we have made this model accessible via a web server at http://uhccnet.com/ for ease of use. The integration of multiphase CT images with deep learning-generated heatmaps for predicting treatment response provides a robust and practical tool for guiding CLICI therapy in patients with unresectable HCC.
- | Journal: Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. (Pubmed Central) - Apr 15, 2024
This study aimed to develop and validate an LC-MS/MS method for the simultaneous quantification of 11 OADs (gefitinib, imatinib, lenvatinib, regorafenib, everolimus, osimertinib, sunitinib, tamoxifen, lapatinib, fruquintinib and sorafenib) and 2 active metabolites (N-desethyl sunitinib and Z-endoxifen) in human plasma. The intra- and inter-day imprecision was below 12.81
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Review, Journal, Metastases: Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis. (Pubmed Central) - Apr 15, 2024
TSA suggested that the available data were adequate for drawing numerical conclusions regarding ORR and DCR. An approach combining TACE, lenvatinib, and PD-1 inhibitors appeared to offer significant improvements in OS, PFS, ORR, and DCR in patients with advanced HCC without significantly increasing the risk for all-grade adverse events.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Novel chiral matrine derivatives as potential antitumor agents: Design, synthesis and biological evaluation. (Pubmed Central) - Apr 15, 2024
In vivo, experiments demonstrated that Q12 exhibited a higher tumor growth inhibition rate (TGI) compared to the positive control drug Lenvatinib, while maintaining good safety. In summary, it suggests that Topo I might be a potential target for matrine and Q12 represents a promising candidate for cancer treatment.
- | New P3 trial: CARE1 Pragmatic Clinical Trial (clinicaltrials.gov) - Apr 14, 2024
P3, N=1250, Not yet recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Noninvasive Visualization of Tumor Blood Vessels within Hepatocellular Carcinoma by Application of Superb Microvascular Imaging to Contrast-Enhanced Ultrasonography. (Pubmed Central) - Apr 13, 2024
We performed a noninvasive time-course evaluation of vascular normalization after lenvatinib administration by applying SMI. The evaluation of vascular normalization with lenvatinib therapy using CEUS and SMI can support the decision to proceed to conversion therapies.
- || Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Review, Journal: Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives. (Pubmed Central) - Apr 13, 2024
Given the absence of specific guidelines, endoscopic surveillance during treatment is advisable, and primary and secondary prophylaxis of variceal bleeding should adhere to the Baveno VII recommendations. Furthermore, in patients with advanced HCC, refinement of diagnostic criteria for CSPH and guidelines for its surveillance are warranted.
- || Inlyta (axitinib) / Pfizer, AiTan (rivoceranib) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma. (Pubmed Central) - Apr 12, 2024
On the contrary, some patients with mucosal, acral or KIT-mutant melanoma may benefit from TKI-based therapies. Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma.
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC (clinicaltrials.gov) - Apr 12, 2024
P2, N=20, Recruiting, Sponsor: Sulai Liu
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov) - Apr 11, 2024
P2, N=300, Recruiting, Sponsor: Peking Union Medical College Hospital
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: SCALE: Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC (clinicaltrials.gov) - Apr 11, 2024
P2, N=30, Not yet recruiting, Sponsor: Hui-Chuan Sun
- || Review, Journal: Update of the German S3 guideline on renal cell carcinoma (Pubmed Central) - Apr 11, 2024
Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma. The S3
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Is this also abscopal effect, or something else? A case of TACE with atezolizumab-bevacizumab for hepatocellular carcinoma with shrinkage of distant metastasis after TACE to the primary liver lesion () - Apr 10, 2024 - Abstract #ECIO2024ECIO_531;
Three weeks after TACE, Atez-Bev combination therapy was resumed. Two months after TACE, multiple lung metastasis shrank along with the intrahepatic lesions on CT scan.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Achieving hemostasis by TACE in Lenvatinib induced tumor rupture in a case of multifocal Hepatocellular carcinoma () - Apr 10, 2024 - Abstract #ECIO2024ECIO_528;
Because the patient was stable, it was decided perform an interventional treatment TACE using Doxorubicin-lipidol combination and PVA particles. Close monitoring and careful management are needed in the first 1
- Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Transarterial chemoembolization combined with Lenvatinib plus Tislelizumab for unresectable hepatocellular carcinoma: A retrospective study () - Apr 10, 2024 - Abstract #ECIO2024ECIO_508;
Close monitoring and careful management are needed in the first 1 OS and PFS were significantly improved in patients who received TLT compared to those who received TL, patients with more than 3 tumors, a maximum tumor > 7cm, and PVTT appeared to derive more benefit.
- Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Analyzing the significance of the Prognostic Nutritional Index (PNI) score in HCC patients undergoing Lenvatinib with or without Tislelizumab as a novel biomarker () - Apr 10, 2024 - Abstract #ECIO2024ECIO_471;
PNI score, as a novel biomarker for predicting response to Lenvatinib with or without Tislelizumab, can effectively predict survival. Patients with a low PNI score have poor survival.
- ||| Retrospective data, Review, Journal, Adverse events, Checkpoint inhibition, Metastases: Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis. (Pubmed Central) - Apr 10, 2024
The analysis focused on the probability of irAEs occurrence in each system when mRCC patients were treated with different ICI-based therapies, potentially offering significant value for guiding clinical prevention, early diagnosis, and management of irAEs. The limitations of the study included the potential heterogeneity and low certainty of part of the evidence.
- | Lumakras (sotorasib) / Amgen, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial withdrawal, Metastases: AMBER: AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC (clinicaltrials.gov) - Apr 9, 2024
P2, N=0, Withdrawn, Sponsor: ETOP IBCSG Partners Foundation
The limitations of the study included the potential heterogeneity and low certainty of part of the evidence. N=47 --> 0 | Not yet recruiting --> Withdrawn
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: LENVABLA: Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative (clinicaltrials.gov) - Apr 8, 2024
P2, N=32, Active, not recruiting, Sponsor: Assistance Publique - H
N=47 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=50 --> 32 | Trial completion date: Feb 2025 --> Oct 2026 | Trial primary completion date: Apr 2024 --> Jul 2025
- || Review, Journal, Metastases: The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers. (Pubmed Central) - Apr 8, 2024
Recruiting --> Active, not recruiting | N=50 --> 32 | Trial completion date: Feb 2025 --> Oct 2026 | Trial primary completion date: Apr 2024 --> Jul 2025 So far, ICI-TKI combinations with nivolumab
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
P3 data, Journal, Metastases: Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. (Pubmed Central) - Apr 8, 2024
Treatment-emergent adverse events occurred in >90% of patients who received either treatment. In conclusion, lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in treatment-na
- | Phase classification, Combination therapy, Monotherapy: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=80, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
In conclusion, lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in treatment-na Phase classification: P1b/2 --> P1/2
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New trial, HEOR, Real-world evidence: CA209-1275: Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients (clinicaltrials.gov) - Apr 4, 2024
P=N/A, N=350, Recruiting, Sponsor: Bristol-Myers Squibb
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal: Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib. (Pubmed Central) - Apr 4, 2024
In contrast, a higher-than-median PLR (?142.1) was associated with shorter OS compared to a lower PLR (P=0.039). Baseline inflammatory biomarkers can serve as predictive indicators of PFS and OS in patients with RAI-refractory thyroid cancer treated with lenvatinib.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. (Pubmed Central) - Apr 3, 2024
Therapeutically, significant and durable tumor regression and survival benefit were achieved with 177Lu- and 225Ac-labeled RAYZ-8009, as single agents and in combination with lenvatinib, in GPC3-positive HCC xenografts. Preclinical in